MPOWERED: Patients with acromegaly, aged 18-75 y, treated with iSRLs for at least 6 mo (stable dose >4 mo) with biochemical control (mean IGF-1 <1.3 ULN and mean integrated GH <2.5 ng/mL at screening). Combination Sub-Study (cabergoline + OOC): failure to respond to 80 mg/d OOC for >2 w during the 26-w run-in phase, inadequate biochemical response and ineligible to enter the ROT phase on 80 mg/d OOC. The gene discussed is IGF1; the disease is acromegaly.